QiJiong Li

1.9k total citations · 2 hit papers
33 papers, 1.3k citations indexed

About

QiJiong Li is a scholar working on Hepatology, Pathology and Forensic Medicine and Surgery. According to data from OpenAlex, QiJiong Li has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hepatology, 15 papers in Pathology and Forensic Medicine and 10 papers in Surgery. Recurrent topics in QiJiong Li's work include Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Cancer Mechanisms and Therapy (13 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers). QiJiong Li is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Cancer Mechanisms and Therapy (13 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (9 papers). QiJiong Li collaborates with scholars based in China and United States. QiJiong Li's co-authors include Ming Shi, Minke He, Rong Guo, Li Xu, Wei Wei, Yong Le, Ruhai Zou, MinShan Chen, ZhiCheng Lai and Zhongguo Zhou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Hepatology.

In The Last Decade

QiJiong Li

32 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

2019 372 citations Minke He, QiJiong Li et al. profile →
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial

2022 119 citations ZhiCheng Lai, Minke He et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
QiJiong Li China	18	919	463	382	302	297	33	1.3k
Minke He China	14	799 0.9×	412 0.9×	313 0.8×	230 0.8×	234 0.8×	41	1.1k
Hirokazu Chishina Japan	18	900 1.0×	275 0.6×	199 0.5×	378 1.3×	225 0.8×	44	1.1k
Florian Hucke Austria	13	1.0k 1.1×	286 0.6×	281 0.7×	499 1.7×	235 0.8×	28	1.3k
Bin‐Yan Zhong China	17	660 0.7×	234 0.5×	246 0.6×	256 0.8×	221 0.7×	74	1.0k
Akinobu Tawada Japan	21	852 0.9×	170 0.4×	209 0.5×	583 1.9×	169 0.6×	69	1.2k
Wen‐Feng Gong China	14	800 0.9×	140 0.3×	277 0.7×	436 1.4×	324 1.1×	29	1.1k
Jong Young Choi South Korea	18	899 1.0×	132 0.3×	315 0.8×	397 1.3×	171 0.6×	33	1.1k
Bolorsukh Gansukh United States	6	421 0.5×	164 0.4×	156 0.4×	246 0.8×	261 0.9×	8	847
Ghalib Jibara United States	17	933 1.0×	117 0.3×	734 1.9×	482 1.6×	378 1.3×	37	1.7k
Guosheng Tan China	12	352 0.4×	193 0.4×	177 0.5×	124 0.4×	125 0.4×	29	852

Countries citing papers authored by QiJiong Li

Since Specialization

Citations

This map shows the geographic impact of QiJiong Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by QiJiong Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites QiJiong Li more than expected).

Fields of papers citing papers by QiJiong Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by QiJiong Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by QiJiong Li. The network helps show where QiJiong Li may publish in the future.

Co-authorship network of co-authors of QiJiong Li

This figure shows the co-authorship network connecting the top 25 collaborators of QiJiong Li. A scholar is included among the top collaborators of QiJiong Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with QiJiong Li. QiJiong Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Yujie, Na Liu, QiJiong Li, et al.. (2025). Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma. Frontiers in Immunology. 16. 1573098–1573098.

Kan, Anna, Minke He, Huifang Li, et al.. (2024). Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. Frontiers in Immunology. 15. 1260191–1260191. 9 indexed citations

He, Minke, ZhiCheng Lai, QiJiong Li, et al.. (2023). Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Current Opinion in Pharmacology. 70. 102362–102362. 8 indexed citations

Lai, ZhiCheng, JingXian Shen, QiJiong Li, et al.. (2023). Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC). Clinical Cancer Research. 29(24). 5104–5115. 17 indexed citations

Lai, ZhiCheng, Minke He, Yu-Jie Xu, et al.. (2022). Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. European Journal of Cancer. 174. 68–77. 119 indexed citations breakdown →

He, Minke, Chuan Peng, Yang Zhao, et al.. (2021). Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunology Immunotherapy. 70(11). 3207–3216. 25 indexed citations

Zhao, Yang, Minke He, Dongsheng Wen, et al.. (2021). Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Frontiers in Oncology. 11. 619461–619461. 14 indexed citations

Zhao, Yang, et al.. (2021). Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin. Therapeutics and Clinical Risk Management. Volume 17. 73–77. 1 indexed citations

Le, Yong, Anna Kan, QiJiong Li, et al.. (2019). NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma. Cancer Cell International. 19(1). 228–228. 23 indexed citations

10.

Le, Yong, Jingxian Shen, Yongfa Zhang, et al.. (2019). Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. Journal of Cancer. 10(3). 665–671. 12 indexed citations

11.

Li, QiJiong, et al.. (2019). Clinical practice of basin-shaped hepaticojejunostomy following hilar resection of stage III/IV hilar cholangiocarcinoma. BMC Gastroenterology. 19(1). 99–99. 4 indexed citations

12.

He, Minke, Ruhai Zou, QiJiong Li, et al.. (2018). Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. CardioVascular and Interventional Radiology. 41(5). 734–743. 39 indexed citations

13.

Tan, Xuying, QiJiong Li, Gong‐Cheng Liao, et al.. (2018). Trimethylamine N-oxide, a gut microbiota-dependent metabolite of choline, is positively associated with the risk of primary liver cancer: a case-control study. Nutrition & Metabolism. 15(1). 81–81. 53 indexed citations

14.

Li, QiJiong, Weihua Li, Wencong Wang, et al.. (2017). Comparison of Two Rabbit Models with Deficiency of Corneal Epithelium and Limbal Stem Cells Established by Different Methods. Tissue Engineering Part C Methods. 23(11). 710–717. 9 indexed citations

15.

He, Minke, Yong Le, QiJiong Li, et al.. (2017). Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chinese Journal of Cancer. 36(1). 83–83. 105 indexed citations

16.

Li, QiJiong, Xiaofeng Liu, Kemin Jin, et al.. (2017). NAT10 is upregulated in hepatocellular carcinoma and enhances mutant p53 activity. BMC Cancer. 17(1). 70 indexed citations

17.

Liao, Yadi, Yun Zheng, Wei He, et al.. (2016). Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncology Letters. 13(2). 984–992. 17 indexed citations

18.

He, Wei, Binkui Li, Yun Zheng, et al.. (2016). Resection vs. ablation for alpha‐fetoprotein positive hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver International. 36(11). 1677–1687. 18 indexed citations

19.

Qiu, Jiliang, Yun Zheng, Jingxian Shen, et al.. (2015). Resection versus ablation in hepatitis B virus−related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery. 158(5). 1235–1243. 14 indexed citations

20.

Huang, Jun, QiJiong Li, Yun Zheng, et al.. (2014). Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC Cancer. 14(1). 818–818. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact